PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVasopressin
Vasopressin
Pitressin, Vasopressin, Vasostrict (vasopressin) is a protein pharmaceutical. Vasopressin was first approved as Pitressin tannate on 1982-01-01.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vasopressin, Vasostrict (discontinued: Pitressin, Vasopressin, Vasostrict)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vasopressin
Tradename
Company
Number
Date
Products
VASOPRESSINAmerican RegentN-212593 RX2020-08-03
2 products, RLD, RS
VASOPRESSIN IN SODIUM CHLORIDE 0.9%BaxterN-217569 RX2023-09-29
2 products, RLD, RS
VASOSTRICTEndoN-204485 RX2014-04-17
4 products, RLD, RS
VASOPRESSIN IN SODIUM CHLORIDE 0.9%Long Grove PharmaceuticalsN-217766 RX2024-07-11
2 products, RLD, RS
Show 2 discontinued
Vasopressin tannate
Tradename
Company
Number
Date
Products
PITRESSIN TANNATEPfizerN-003402 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vasopressinANDA2025-06-25
vasopressin in 0.9% sodium chlorideNew Drug Application2025-06-17
vasostrictNew Drug Application2023-11-16
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Vasopressin, Vasostrict, Par Sterile Products
93754782035-01-30U-1857
96875262035-01-30U-1857
97442092035-01-30U-1857
97442392035-01-30U-1857
97507852035-01-30DP
99190262035-01-30DP
99252332035-01-30U-1857
99252342035-01-30U-1857
99372232035-01-30U-1857
99624222035-01-30U-1857
99686492035-01-30U-1857
99748272035-01-30U-1857
99810062035-01-30U-1857
100105752035-01-30U-1857
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03X: Other diuretics in atc
— C03XA: Vasopressin antagonists, diuretics
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BA: Vasopressin and analogues
— H01BA01: Vasopressin (argipressin)
HCPCS
No data
Clinical
Clinical Trials
469 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyponatremiaD007010—E87.1242681756
Heart failureD006333EFO_0003144I50271313843
ShockD012769—R57.1112991743
Diabetes insipidusD003919—E23.227632441
Kidney diseasesD007674EFO_0003086N08112152332
Septic shockD012772—A48.3—8681332
Polycystic kidney diseasesD007690—Q61.3—10152430
Autosomal dominant polycystic kidneyD016891EFO_1001496Q61.2—10132428
Healthy volunteers/patients———131—11227
Liver cirrhosisD008103EFO_0001422K74.01792523
Show 61 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Inappropriate adh syndromeD007177EFO_1000982E22.2127—716
FibrosisD005355——149—316
Neurogenic diabetes insipidusD020790——131—712
EdemaD004487—R60.9135——9
Autism spectrum disorderD000067877—F84.0432——8
Wounds and injuriesD014947—T14.8221—38
Autistic disorderD001321EFO_0003758F84.0232——6
Chronic renal insufficiencyD051436—N18—32——5
Cardiac edemaD004489EFO_1001771———5——5
Pervasive child development disordersD002659EFO_0003756F842—1——3
Show 28 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13—3——69
StrokeD020521EFO_0000712I63.923——27
Chronic kidney failureD007676EFO_0003884N18.6—4——15
Critical illnessD016638———1——45
Nephrogenic diabetes insipidusD018500—N25.1—1——34
Brain edemaD001929EFO_1000845G93.611——13
NephritisD009393—N05—2———2
Cerebral hemorrhageD002543——11———2
Pulmonary hypertensionD006976EFO_0001361I27.20—1——12
Traumatic shockD012774—T79.411———2
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain injuriesD001930—S06.91———23
Social psychologyD011593——2————2
Liver transplantationD016031EFO_0010682—1———12
ThrombosisD013927——1———12
Traumatic brain injuriesD000070642—S061———12
Pure autonomic failureD054970——1————1
TachycardiaD013610—R00.01————1
Prostatic neoplasmsD011471—C611————1
NephrolithiasisD053040—N20.01————1
Kidney calculiD007669EFO_0004253N201————1
Show 7 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver failureD017093—K72.9————44
DehydrationD003681—E86.0————33
Hepatic insufficiencyD048550——————33
Blood platelet disordersD001791——————22
Type 2 diabetes mellitusD003924EFO_0001360E11————22
Pituitary diseasesD010900—E23.7————22
Cardiogenic shockD012770—R57.0————22
SchizophreniaD012559EFO_0000692F20————22
BurnsD002056—T30.0————22
Acute liver failureD017114——————22
Show 93 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVasopressin
INNvasopressin injection
Description
Argipressin is the predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. It has a role as a cardiovascular drug, a hematologic agent and a mitogen. It is a conjugate base of an argipressin(2+).
Classification
Protein
Drug classvasoconstrictors (vasopressin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Identifiers
PDB—
CAS-ID113-79-1
RxCUI—
ChEMBL IDCHEMBL373742
ChEBI ID34543
PubChem CID644077
DrugBankDB00067
UNII IDY87Y826H08 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vasopressin – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 61,207 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,954 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use